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ABSTRACT 
The remarkable progress in cancer immunotherapy in recent years has led to the heat of great 
development for therapeutic antibodies. Antibody numbering, which standardizes a residue 
index at each position of an antibody variable domain, is an important step in 
immunoinformatic analysis. It provides an equivalent index for the comparison of sequences 
or structures, which is particularly valuable for antibody modeling and engineering. However, 
due to the extremely high diversity of antibody sequences, antibody numbering tools cannot 
work in all cases. This article introduces a new antibody numbering tool named AbRSA, 
which integrates heuristic knowledge of region-specific features into sequence mapping to 
enhance the robustness. The benchmarks demonstrate that, AbRSA exhibits robust 
performance in numbering sequences with diverse lengths and patterns compared with the 
state-of-the-art tools. AbRSA offers a user-friendly interface for antibody numbering, 
complementarity-determining region (CDR) delimitation and 3D structure rendering. It is 
freely available at http://cao.labshare.cn/AbRSA/. 
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Abbreviations 
CDR: complementarity determining region 
FR: framework region 
HMM: Hidden Markov Model  
V gene: variable gene 
D gene: diversity gene 
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J gene: joining gene  
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Introduction  
Antibodies, or immunoglobulins, are extremely important proteins in the immune system that 
can identify and neutralize antigens due to their unique sequence composition of two 
identical pairs of heavy and light chains. Each pair contains a constant domain and a variable 
domain. The latter forms antigen-binding sites and determines binding specificity and affinity. 
The sequence of the variable domain is highly diverse, resulting from the rearrangement of a 
variable (V) gene, a diversity (D) gene and a joining (J) gene (or a J gene and a V gene). The 
variable domain can be further divided into two types of regions: 
complementarity-determining regions (CDRs) and framework regions (FRs). CDRs exhibit a 
direct relationship with antigen binding, while FRs provide support to the CDR conformation. 
The general 3D structure of all variable domains is very similar, folding into a group of 
beta strands linked by loops.1 Six of the loops at the top are the CDRs (CDR H1/2/3 in the 
heavy chain and CDR L1/2/3 in the light chain). Because of the regularity of the structure, it 
is highly beneficial to number each residue using a standard scheme for sequence 
comparisons and engineering, for example, to facilitate the description of critical residues and 
to delimit CDRs for humanization.2-12 Antibody numbering has become a fundamental 
technique used in immunoinformatic analyses. The first numbering scheme, known as the 
Kabat scheme, was introduced in 1970.13 In subsequent years, the Chothia scheme14-16 and its 
variants,17 such as the IMGT18 and AHo19 schemes, were introduced. These schemes are 
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similar but vary in the numbering of some insertion and deletion positions. The Kabat scheme 
is based on sequence patterns, while in the Chothia scheme, the definition is modified by 
incorporating structural information. IMGT and AHo unify the numbering of antibodies and 
T-cell receptors. 
Antibody numbering is generally achieved by mapping a query sequence onto known 
sequences that have been numbered in advance. The state-of-the-art software used for 
antibody numbering introduces complicated strategies. For example, AbNum17 built the 
profiles of six residues at the start and end of FRs as anchor regions. For a query sequence, 
AbNum searches for the anchor regions and aligns the other regions to known sequences, 
which finally determine the numbering. IgBlast and the germline knowledge-based approach 
are used to perform sequence alignment against pre-annotated databases of germline genes 
and map the numberings to the query sequence.20,21 Other software options, such as 
ANARCI,22 PyIgClassify,23 ProABC24 and DIGIT,25 pre-annotated a large set of antibody 
sequences, and made sequence alignment to build hidden Markov models (HMMs). Then 
query sequences were aligned to the HMMs and annotated by transferring the numbering of 
equivalent position from known sequence to the query. These software tools have 
successfully numbered lots of antibody sequences. However, antibody sequences are highly 
diverse. If the query sequence has no known anchor residues or similar patterns they cannot 
be numbered with these software. This has been observed in many benchmark tests, for 
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example, 1%~2% antibody sequences of Kabat databases cannot be numbered by AbNum.17 
9,560 in 1,936,119 VH sequences cannot be numbered by ANARCI.22 Although the error 
rates (2%~0.5%) are small, the absolute value of errors is large because the cardinality of 
antibody sequences is huge. Besides, the latest developed antibody technology obtained 
sequences not only in vivo as before but also in vitro, which further creates the divergence.26 
Therefore, no matter for high throughput analysis or individual inspection, it is valuable to 
develop more robust antibody numbering tools.  In this work, we introduce heuristic 
knowledge into sequence mapping and propose a new method, referred to as the Antibody 
Region-Specific Alignment (AbRSA), which improves robustness when numbering 
antibodies with diverse patterns accord to our benchmark tests. In order to serve as an 
easy-to-use tool, AbRSA offers a user-friendly interface that can identify whether a query 
sequence is an antibody heavy or light chain, how the sequence is numbered and which region 
is the CDR. AbRSA provides a new option for immunoinformatic analyses. 
 
Results 
The popular antibody numbering methods are mainly classified into sequence-alignment 
based or HMM based numbering. Both of them require a large collection of pre-annotated 
antibody sequences to build the library or model for sequence mapping. The dependence on 
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pre-annotated sequences achieves success in known patterns but fails in irregular ones. 
AbRSA belongs to the sequence-alignment based method. In order to enhance the robustness, 
it divides the sequences into segments, which allows the lower weights in more diverse 
regions, particularity CDRs, and higher weights in the conserved regions (see Materials and 
Methods). In this section, we will describe the results of AbRSA on the benchmark set and 
simulated set, and compared the results with three state-of-the-art tools. Also we will 
introduce its online usage to facilitate users which are not experts in programming.  
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Testing AbRSA on the benchmark set 
To assess the overall performance, AbRSA is applied to the benchmark set, which includes 
1816 pre-annotated antibody sequences collected from Protein Data Bank and has no overlaps 
with the training sequences (see Materials and Methods). The results show that AbRSA 
numbered all the sequences, while the AbRSA without region-specific deviation only 
numbered 83.6% sequences. By comparing the pre-annotated numbering with the results of 
the two programs, AbRSA shows identical numberings except one mismatch of a heavy chain 
(PDB code: 4I3R), while the AbRSA without region-specific deviation failed in 13.0% 
numbered sequences. This result indicates that the region-specific alignment is superior to the 
pure sequence-alignment method.  
For comparison, three state-of-the-art programs (AbNum, ANARCI and an integrated tool 
in proABC) are applied to the same benchmark set. AbNum employs a sequence-profile 
matching method, while ANARCI and proABC use HMMs for sequence numbering. 
proABC, AbNum and ANARCI were unable to number 22, 32, and 8 heavy chains and 8, 5 
and 0 light chains, respectively (see Table 1). By comparing the results with pre-annotated 
numberings, proABC and ANARCI show 16 and 4 mismatches, respectively. These results 
imply that it is a particularly difficult task to number every antibody sequence using program 
tools.  
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Detailed analysis shows that those unsuccessful numbering sequences exhibit two types of 
features in CDRs: pseudo-conserved patterns and unusual lengths. For example, the WGTE 
segment in CDR H3 appears similar to the conserved pattern WGXG (where X represents 
any type of amino acid), and the SGGG segment in CDR L3 is similar to conserved pattern 
FGXG in FR, which tend to mislead the pattern recognition (Fig. 1). Another types are the 
ultra-long CDR H3 (>25 residues) and the ultra-short CDR H1 (<4 residues), which are quite 
different from the regular patterns. These unusual sequences cannot be recognized if there is 
no additional information to guide the program. AbRSA classifies the sequence into regions 
and attempts to number them using the general pattern recognition in CDRs and the precise 
pattern recognition in FRs. This is the reason that AbRSA can number these sequences, even 
though their pseudo-conserved patterns and ultra-lengths of CDRs are not included in the 
consensus sequences or training sequence set. 
 
Testing robustness: increasing diversities of antibody sequences 
The benchmark test shows that AbRSA can number antibodies with unusual patterns. 
However, its maximum performance for diverse sequences remains unknown. Hence, we 
employed a well-established antibody sequence simulation model AB33 to generate a huge 
simulated antibody set (187,200 heavy chains and 70,200 light chains) in order to expand the 
diversity of benchmark sequences (see Materials and Methods). Briefly, random mutations 
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are introduced in antibody sequences using a transition probability matrix to mimick somatic 
hypermutations. The number of mutation is gradually increased from 10 to 50 with a step of 5. 
The more mutations imply the larger diversity of the sequence. We applied AbRSA to this 
simulated set. When the number of mutations in heavy chains is less than 10, the success rate 
of numbering is 100%. As the number further increases, the success rates decrease from 
99.5%, 98.9%, 97.7%, 96.7%, 95.2%, 94.0% and 91.6% to 90.6% in the end, which changes 
half of the original antibody sequence [Fig. 2(A)]. Similarly, when the numbers of mutations 
in light chains are less than 30, the success rates keep 100%. As the number further increases, 
the success rate slightly decreased from 99.2%, 99%, 98.6% and 97.0% to 96.3% [Fig. 2(B)]. 
For comparison, we also applied ANARCI and AbNum to the simulated set (see Testing 
methods in Materials and Methods). In case of heavy chains, the success rates shows the 
similar trend to AbRSA when the number of mutation increases. However, ANARCI and 
AbNum accumulates more unsuccessful numberings, especially in the end, when introducing 
more mutations in a sequence, the success rate decreases to 82.7% and 60.7%, respectively, 
which is 8.1% and 30.0% less than AbRSA. In case of light chains, ANARCI and AbNum 
also accumulate more unsuccessful numberings than AbRSA. In the end, the success rate is 
90.2% and 74.5% while that of AbRSA is 96.3% [Fig. 2(A), 2(B)]. This result shows that 
AbRSA was rather robust to the simulated somatic hypermutations, due to the prior 
knowledge of the region-specific feature. 
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 Testing specificity: distinguishing between antibodies and non-antibodies 
AbRSA shows highly robust performance for antibody sequence variations in the above test. 
Then, the question arises of whether AbRSA can distinguish between antibodies and 
non-antibodies, which is critical for application to unknown sequences. To answer this 
question, we compared the alignment results for both antibody and non-antibody sequences. 
The former are obtained from the benchmark data, which included 1,816 heavy or light 
chains. The latter are from the Swiss-Prot database,27 including 551,744 sequences, excluding 
those annotated as antibodies, V genes, immunoglobulins, or heavy or light chains. The 
alignment results are quantified based on the sequence identity between the query and 
consensus sequences. As CDRs exhibit diverse lengths, which may affect the results, we 
quantified the sequence identity in FRs, rather than the whole sequence.  
  The result is illustrated in Figure 3, which shows the frequency distribution of the sequence 
identities. There are two peaks in the figure. The black curve indicates non-antibodies, whose 
average sequence identity is approximately 38%, ranging from 0-66%. The gray curve 
indicates antibodies, whose average sequence identity is approximately 94%, ranging from 
74-100%. The non-overlapping curves demonstrate that AbRSA can clearly distinguish 
between antibody and non-antibody sequences. We checked the four non-antibodies 
exhibiting the highest sequence identity (≥65%) and found that they were 
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immunoglobulin-like proteins, but not real antibodies. For comparison, we also assessed the 
performance of ANARCI and AbNum using the non-antibody set (see Testing methods in 
Materials and Methods). The result shows that ANARCI identified all the sequences as 
non-antibody, while AbNum identified most non-antibodies except a viral T-cell receptor 
beta chain-like protein (UniProt ID: P11364) that was recognized as the light chain of 
antibody. 
 
Web service of AbRSA 
To make the best use of AbRSA, we set up a user-friendly web service. AbRSA is 
implemented in C++ and PHP. The AbRSA pipeline for computation is shown in Figure 4. 
The input could be either the protein sequence or structure. Multiple protein sequences are 
supported if the sequences are in FASTA format. The input will then be subjected to 
region-specific alignment with heavy- and light-chain consensus sequences (see supporting 
information). The program will judge whether the sequence is a heavy chain or light chain, or 
neither, by comparing sequence identities with consensus sequences. If the identities are 
lower than the cutoff (70%, minimum value from the training set), the query sequence will 
not be recognized as an antibody, and the program will loop back to search for more heavy or 
light chains in the query sequence in the case of fusion proteins, which may contain multiple 
antibody variable domains. After all possible heavy or light chains are found; the program 
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will output the numbering results and the location of FRs and CDRs in the sequences. If the 
input is a protein structure (PDB format file), the web server will extract protein sequences 
and subject to region-specific alignment with heavy- and light-chain consensus sequences as 
the above process. In addition, it uses an interactive molecular visualization JavaScript library, 
called 3Dmol.js,28 to render three-dimensional (3D) graphics in the web browser. It highlights 
the residues of CDRs according to the numbering results using different colors in the 3D 
graphics. As 3Dmol is hardware-accelerated, the 3D view can be rotated, translated, and 
re-sized by dragging and scrolling the mouse smoothly. This feature could help to determine 
the location and conformation of CDRs. 
 
Discussion  
Antibody sequence numbering is a well-established, but critical topic in the field of antibody 
research. AbRSA can complement existing methods by focusing on unusual antibody 
sequences. Traditionally, the performance of antibody numbering is related to the amount of 
sequences used for method training. Recently developed methods employing a larger training 
set can number more antibodies than earlier methods. However, these methods may not be 
applicable to unusual sequences. Integrating additional biological insights, beyond the 
sequences themselves, could solve the problem. In this report, we show that AbRSA is very 
robust to unusual antibodies whose patterns are not included in the training data, indicating 
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that the region-specific features contribute to antibody numbering. The current AbRSA tool 
supports a Kabat and Chothia numbering scheme. In the future, we will continuously improve 
our program and provide additional numbering schemes to the user. 
 
 
Materials and Methods 
Training set  
The training dataset consisted of antibody sequences downloaded from the UniProt 
database.29 Redundant sequences were eliminated using CD-HIT30 with a sequence identity 
cutoff of 85%. In total, 503 heavy and 475 light chains were collected. All sequences were 
numbered and double checked by using two well-established programs, AbNum and 
ANARCI. The sequences that could not be numbered by the programs were discarded. 
Benchmark set 
All the antibodies were collected from the Protein Data Bank.31 The redundant sequences 
were removed by CD-HIT. To avoid overlap of the benchmark and training datasets, the 
sequence whose identity was over 85% (the average identity for any pair of antibody 
sequences that we knew) were also removed. In total, 983 heavy and 833 light chains were 
obtained. The pre-annotated numbering was obtained using AbNum and ANARCI. 39 chains 
could not be numbered (no output) by both software, and 13 chains showed conflicting 
results. Those sequences were manually numbered using 3D structure alignments.32 
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Simulated set  
To expand the diversity of benchmark sequences, a well-established antibody sequence 
simulation model AB33 is used to generate the simulated set in two steps. Firstly, the 
benchmark set is clustered using a sequence similarity cutoff of 80% by CD-HIT. One 
representative sequence in each cluster was randomly selected as the starting sequence of 
simulation. The sequences that could not be numbered by AbNum and ANARCI are 
eliminated. In all, 208 heavy and 78 light chains were obtained. Secondly, random mutations 
are introduced in these sequences using the antibody-specific amino acid substitution model 
AB, which is guided by 20×20 matrix of replacement rates between amino acids. The number 
of mutations is gradually increased from 10 to 50 with a step of 5. Each of the steps is 
repeated 100 times which finally create 900×208=187,200 heavy chains and 900×78=70,200 
light chains. 
Antibody region-specific alignment method 
Antibody sequence diversity is mainly generated through two processes: somatic 
recombination and hypermutation.34,35 The former joins the alleles of V, D and J genes or 
those of only V and J genes randomly. The regions where the genes recombine are located in 
CDR H3 and CDR L3, resulting in the diverse lengths of these regions. The latter process 
consists of frequent random mutations, which often occur at CDRs. As a result, CDRs exhibit 
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frequent substitutions, insertions and deletions, while FRs generally show a small number of 
substitutions. The origin of diversity tells us the variability of antibody is region specific. 
Although it has been implicitly incorporate in previous methods, region specific feature has 
not been taken full advantage yet. Hence we tried to strengthen the feature explicitly by using 
different alignment strategy in each region of the consensus sequence of antibody. Two 
consensus sequences (see supporting information) of heavy and light chains came from the 
antibody database abYsis,36 where the residue distribution in variable domains is analyzed. 
The two consensus sequences were numbered by the standard numbering scheme of Kabat 
and Chothia. The sequences were divided into four types of regions: (1) FRs; (2) CDRs; (3) 
insertion positions (IPs) following the definition of the numbering scheme, such as H82 and 
L95 in the Chothia scheme (see supporting information); and (4) conserved positions (CPs), 
where one or two amino acids show a frequency above 95%, such as cysteine at H22 and 
aspartic acid at L82 in the Chothia scheme (see supporting information). These four types 
allow region-dependent features to be incorporated into sequence mapping. 
  To number an antibody, we employed a modified Needleman-Wunsch dynamic 
programming algorithm37 to map the query sequence to the consensus sequence. The score at 
each position in the alignment is calculated as follows:  
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  (1) 
where 
                        (2) 
and 
                         (3) 
In the above equations, i is the residue index of the query sequence, and j is the residue index 
of the consensus sequence. The alignment score (max{Blosum62(i, j)}) is calculated by 
enumerating BLOSUM62 matrix for query residue and all possible residues at a given 
position of the consensus sequence. PCPs, PIPs, PFRs and PCDRs are the gap penalties at CPs, IPs, 
FRs and CDRs, respectively. SCPs is the weight of the match score at CPs. The total score is 
the summation of S(i,j) at each position. We explored the combination of SCPs, PIPs, PCPs, PFRs 
and PCDRs by iterating their values from 0 to 100 using the training set. 
  We found that the best numbering performance (100% identical to pre-annotated 
numbering) for the training data was achieved when PIPs=1, PCDRs=11, PFRs=26, PCPs=55 and 
SCPs=5. These parameters are in accordance with the assumption that the gap penalty 
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increases in a step-by-step manner from IPs, to CDRs, FRs and CPs. The scoring weight (SCPs) 
for residues located at CPs was five times greater than that of the other residues.  
Testing methods for ANARCI, AbNum and proABC 
The latest stand-alone version of ANARCI (v1.3) was used in this work. AbNum and 
proABC were tested on their web servers (http://bioinf.org.uk/abs/abnum/, 
http://circe.med.uniroma1.it/proABC/). As using the simulated set (187,200 and 70,200 
sequences) and non-antibody set (551,744 sequences), we used their subsets for testing. The 
subset of simulated set consists of randomly selected 10 out of 100 mutants in each group. It 
includes 187,200×10%=18,720 heavy chains and 70,200×10%=7,020 light chains. The 
success rates of antibody numbering using this subset are consistent with the results using 5% 
sequences. The subset of non-antibody data includes 7,459 sequences that are most similar to 
antibody consensus sequences (share over 45% identities) in the whole non-antibody set. We 
did not use proABC in comparison studies on the simulated set and non-antibody set for the 
reason of time consumption. 
Availability of data and materials 
The web tool, benchmark set and simulated set are freely available to the public at 
http://cao.labshare.cn/AbRSA/ . 
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Table 1.  Results of antibody numbering using the benchmark dataset. The values are 
numbers of failed cases using four software tools. The result was classified as “No output”, 
which means no light or heavy chain is detected by the tool, and “Mismatch”, which indicates 
the predicted CDRs and FRs are not correct, for heavy and light chains according to Kabat or 
Chothia schemes. 
Tool 
Heavy Chain (N=983)  Light Chain (N=833) 
Kabat Chothia  Kabat Chothia 
No output Mismatch No output Mismatch  No output Mismatch No output Mismatch 
proABC 22 12 -a -a  8 4 -a -a 
AbNum 32 0 32 1  5 0 5 0 
ANARCI 8 2 8 2  0 2 0 2 
AbRSA 0 1 0 1  0 0 0 0 
a Software does not support. 
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Figure legends 
 
Figure 1. Examples of pseudo-conserved patterns in CDR3. QueryH and QueryL are heavy- 
and light-chain sequences (PDB code: 4OCR, 3MLT), respectively. Their CDRs are colored 
in blue, and those of CDR3 are underlined. The sky-blue shaded letters “WGTE” and “SGGG” 
in CDR3 are pseudo-conserved patterns, which are similar to real conserved patterns (yellow 
shaded letters “WGQG” and “FGDG”). Pseudo-conserved patterns may mislead numbering 
tools. Please see the sequences as text in the supplementary file.  
 
Figure 2. Benchmark results on simulated set. It illustrates the success rate of simulated 
antibody numbering versus the number of mutations in the original antibodies. A: results for 
heavy chain. B: results for light chain. The black, blue and red lines indicate the results of 
ANARCI, AbNum and AbRSA respectively. 
 
Figure 3. Frequency distribution of the sequence identities of antibodies and non-antibodies. 
The red curve indicates the frequency of sequence identities between antibody queries and 
the consensus sequence. The black curve indicates the frequency of sequence identities 
between non-antibody queries and the consensus sequence. The two curves exhibit no 
overlap, which suggests the antibodies and non-antibodies show obvious differences in 
sequence identity. 
 
Figure 4. A: Pipeline of the AbRSA web service. B: The input of AbRSA. The sequences in 
the textbox are examples. C: The output numbering results of AbRSA using an antibody 
structure (PDB code: 3i75). D: The CDRs are highlighted in colors in the 3D viewer (input 
PDB code: 3i75). 
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